Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition

Cancer Science

Volumn 99, Issue 2, 2008, Pages 272-279

  Sultan, Ahmed S ^a   Brim, Hassan ^b   Sherif, Zaki A ^a,c  

^a GEORGETOWN UNIVERSITY   (United States)

^b HOWARD UNIVERSITY CANCER CENTER   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8; DEXAMETHASONE; ESTROGEN RECEPTOR ALPHA; INSULIN; JANUS KINASE 2; PROLACTIN; PROTEIN ZO1; STAT5A PROTEIN; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VIMENTIN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MESENCHYME; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; EPITHELIAL CELLS; FEMALE; HUMANS; JANUS KINASE 2; MESODERM; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 38949105121     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00685.x     Document Type: Article

References (55)

1. Wakao H, Gouilleux F, Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 1994; 13: 2182-91.
2. Rui H, Kirken RA, Farrar WL. Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J Biol Chem 1994; 269: 5364-8.
3. Dusanter-Fourt I, Muller O, Ziemiecki A et al. Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin-erythropoietin receptor chimera expressed in lymphoid cells. EMBO J 1994; 13: 2583-91.
4. Gilmour KC, Reich NC. Receptor to nucleus signaling by prolactin and interleukin 2 via activation of latent DNA-binding factors. Proc Natl Acad Sci USA 1994; 91: 6850-4.
5. Gouilleux F, Wakao H, Mundt M, Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J 1994; 13: 4361-9.
6. Wagner KU, Krempler A, Triplett AA et al. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol 2004; 24: 5510-20.
7. Liu X, Robinson GW, Hennighausen L. Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol 1996; 10: 1496-506.
8. Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 1995; 92: 8831-5.
9. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997; 11: 179-86.
10. Udy GB, Towers RP, Snell RG et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 1997; 94: 7239-44.
11. Nevalainen MT, Xie J, Bubendorf L, Wagner KU, Rui H. Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol 2002; 16: 1108-24.
12. Liu X, Gallego MI, Smith GH, Robinson GW, Hennighausen L. Functional rescue of Stat5a-null mammary tissue through the activation of compensating signals including Stat5b. Cell Growth Differ 1998; 9: 795-803.
13. Horseman ND, Zhao W, Montecino-Rodriguez E et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 1997; 16: 6926-35.
14. Grimley PM, Dong F, Rui H. Stat5a and Stat5b: Fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev 1999; 10: 131-57.
15. Kabotyanski EB, Rosen JM. Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b. J Biol Chem 2003; 278: 17.218-27.
16. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003; 24: 1-27.
17. Iavnilovitch E, Groner B, Barash I. Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res 2002; 1: 32-47.
18. Canbay E, Norman M, Kilic E, Goffin V, Zachary I. Prolactin stimulates the JAK2 and focal adhesion kinase pathways in human breast carcinoma T47-D cells. Biochem J 1997; 324: 231-6.
19. Stoecklin E, Wissler M, Schaetzle D, Pfitzner E, Groner B. Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol 1999; 69: 195-204.
20. Nevalainen MT, Xie J, Torhorst J et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004; 22: 2053-60.
21. Bratthauer GL, Strauss BL, Tavassoli FA. STAT5a expression in various lesions of the breast. Virchows Arch 2006; 448: 165-71.
22. Tavassoli F, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. France: IARC Press, 2003.
23. Xie J, LeBaron MJ, Nevalainen MT, Rui H. Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells. J Biol Chem 2002; 277: 14.020-30.
24. Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 2004; 108: 665-71.
25. Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 2005; 24: 746-60.
26. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 2006; 66: 1824-32.
27. Topper YJ, Freeman CS. Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev 1980; 60: 1049-106.
28. Merlo GR, Graus-Porta D, Cella N, Marte BM, Taverna D, Hynes NE. Growth, differentiation and survival of HC11 mammary epithelial cells: Diverse effects of receptor tyrosine kinase-activating peptide growth factors. Eur J Cell Biol 1996; 70: 97-105.
29. Lechner J, Welte T et al. Promoter-dependent synergy between glucocorticoid receptor and Stat5 in the activation of α-casein gene trancription. J Biol Chem 1997; 272: 20.954-60.
30. Hoover KB, Liao SY, Bryant PJ. Loss of the tight junction MAGUK ZO-1 in breast cancer: Relationship to glandular differentiation and loss of heterozygosity. Am J Pathol 1998; 153: 1767-73.
31. Sommers CL, Byers SW, Thompson EW, Torri JA, Gelmann EP. Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 1994; 31: 325-35.
32. Sommers CL, Heckford SE, Skerker JM et al. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res 1992; 52: 5190-7.
33. Willott E, Balda MS, Fanning AS, Jameson B, Van Itallie C, Anderson JM. The tight junction protein ZO-1 is homologous to the Drosophila discs-large tumor suppressor protein of septate junctions. Proc Natl Acad Sci USA 1993; 90: 7834-8.
34. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002; 3: 155-66.
35. Humphreys RC, Hennighausen L. Signal transducer and activator of transcription 5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 1999; 10: 685-94.
36. Yamashita H, Iwase H, Toyama T, Fujii Y. Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 2003; 22: 1638-52.
37. Wennbo H, Tornell J. The role of prolactin and growth hormone in breast cancer. Oncogene 2000; 19: 1072-6.
38. Das R, Vonderhaar BK. Prolactin as a mitogen in mammary cells. J Mammary Gland Biol Neoplasia 1997; 2: 29-39.
39. Erwin RA, Kirken RA, Malabarba MG, Farrar WL, Rui H. Prolactin activates Ras via signaling proteins SHC, growth factor receptor bound 2, and son of sevenless. Endocrinology 1995; 136: 3512-18.
40. Gutzman JH, Rugowski DE, Schroeder MD, Watters JJ, Schuler LA. Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells. Mol Endocrinol 2004; 18: 3064-75.
41. Llovera M, Touraine P, Kelly PA, Goffin V. Involvement of prolactin in breast cancer: Redefining the molecular targets. Exp Gerontol 2000; 35: 41-51.
42. Miller SL, DeMaria JE, Freier DO, Riegel AM, Clevenger CV. Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Mol Endocrinol 2005; 19: 939-49.
43. Han Y, Watling D, Rogers NC, Stark GR. JAK2 and STAT5, but not JAK1 and STAT1, are required for prolactin-induced β-lactoglobulin transcription. Mol Endocrinol 1997; 11: 1180-8.
44. Wartmann M, Cella N, Hofer P et al. Lactogenic hormone activation of Stat5 and transcription of the β-casein gene in mammary epithelial cells is independent of p42 ERK2 mitogen-activated protein kinase activity. J Biol Chem 1996; 271: 31.863-8.
45. Trott JF, Hovey RC, Koduri S, Vonderhaar BK. Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. J Mol Endocrinol 2003; 30: 31-47.
46. Hu ZZ, Meng J, Dufau ML. Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. J Biol Chem 2001; 276: 41.086-94.
47. Schaber JD, Fang H, Xu J, Grimley PM, Rui H. Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells. Cancer Res 1998; 58: 1914-19.
48. Acosta JJ, Munoz RM, Gonzalez L et al. Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Mol Endocrinol 2003; 17: 2268-82.
49. Kazansky AV, Raught B, Lindsey SM, Wang YF, Rosen JM. Regulation of mammary gland factor/Stat5a during mammary gland development. Mol Endocrinol 1995; 9: 1598-609.
50. Teglund S, McKay C, Schuetz E et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998; 93: 841-50.
51. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-81.
52. Vincent-Salomon A, Thiery JP. Host microenvironment in breast cancer development: Epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 2003; 5: 101-6.
53. Ikenouchi J, Matsuda M, Furuse M, Tsukita S. Regulation of tight junctions during the epithelium-mesenchyme transition: Direct repression of the gene expression of claudins/occludin by snail. J Cell Sci 2003; 116: 1959-67.
54. Cano A, Perez-Moreno MA, Rodrigo I et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83.
55. Rajasekaran AK, Hojo M, Huima T, Rodriguez-Boulan E. Catenins and zonula occludens-1 form a complex during early stages in the assembly of tight junctions. J Cell Biol 1996; 132: 451-63.